A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
Detailed price information for Metagenomi Therapeutics Inc (MGX-Q) from The Globe and Mail including charting and trades.
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
Explore how gene drives in genetically modified mosquitoes could revolutionize malaria control and combat this deadly disease ...
A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding ...
The National Eligibility cum Entrance Test (NEET-UG) has become the primary gateway for students aspiring to pursue undergraduate medical education in India. While it ensures a standardized selection ...
The scientists driving Neion Bio’s effort to engineer chickens as scalable, lower-cost platforms for biologics manufacturing.
It’s incredible how much our lives have changed over the last 50 years. If you were around back then, you’d remember a world ...
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the emphasis has been on its underlying mechanisms and nucleases. In contrast, ...
To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results